During the ALL Hub Steering Committee meeting in November 2025, key opinion leaders met to discuss strategies to prevent relapse post hematopoietic stem cell transplantation (HSCT) / cellular therapy in B-cell acute lymphoblastic leukemia (B-ALL). The meeting opened with a presentation by Ibrahim Aldoss and featured a discussion including Charles Mullighan, José María Ribera, Sabina Chiaretti, Andre Baruchel, Wendy Stock, Daniel DeAngelo, and Anita Rijneveld.

During his presentation, Aldoss highlighted that despite advances in multi-agent chemotherapy and novel immunotherapies allowing an increased number of patients to undergo allogeneic (allo) HSCT – a potentially curative approach in B-ALL – post-transplant relapse, as well as relapse following CAR T-cell therapy, remains a major cause of treatment failure. He discussed several studies exploring relapse-preventive measures post transplantation, including established strategies such as tyrosine kinase (TKI) maintenance in patients with Philadelphia-chromosome positive (Ph+) ALL, and newer strategies, such as the use of blinatumomab, inotuzumab ozogamicin, or prophylactic donor-derived CAR T-cell therapy, which have shown promising initial activity in patients with B-ALL. He also outlined the major considerations that influence the decision to initiate maintenance therapy after allo-HSCT or salvage therapy post-CAR T-cell therapy.

This educational resource is independently supported by Pfizer. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Carmelo Rizzari, University of Milano-Bicocca, Monza, IT. We asked, How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with acute lymphoblastic leukemia (ALL)?

This educational resource is independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children's Hospital, Salt Lake City, US. We asked, What are the key clinical considerations for asparaginase-based regimens in pediatric vs adolescent/young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.